David Amsellem
Stock Analyst at Piper Sandler
(4.80)
# 495
Out of 4,386 analysts
898
Total ratings
59.7%
Success rate
12.1%
Average return
Main Sectors:
Stocks Rated by David Amsellem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VTRS Viatris | Maintained: Hold | $12 | $15.93 | -24.67% | 24 | Jun 4, 2026 | |
| SUPN Supernus Pharmaceuticals | Maintained: Buy | $66 | $44.57 | +48.10% | 69 | Jun 4, 2026 | |
| AMRX Amneal Pharmaceuticals | Maintained: Buy | $17 | $13.71 | +24.00% | 41 | Jun 4, 2026 | |
| BMY Bristol-Myers Squibb Company | Reiterated: Buy | $75 | $55.57 | +34.96% | 17 | Jun 3, 2026 | |
| JAZZ Jazz Pharmaceuticals | Reiterated: Buy | $301 | $232.04 | +29.72% | 66 | Jun 2, 2026 | |
| ABBV AbbVie | Reiterated: Buy | $298 | $223.07 | +33.59% | 20 | Jun 2, 2026 | |
| CORT Corcept Therapeutics | Reiterated: Buy | $88 | $73.33 | +20.01% | 31 | Jun 1, 2026 | |
| TEVA Teva Pharmaceutical Industries | Reiterated: Buy | $42 | $33.26 | +26.28% | 66 | Jun 1, 2026 | |
| AMGN Amgen | Reiterated: Buy | $427 | $345.73 | +23.51% | 47 | May 29, 2026 | |
| BIIB Biogen | Reiterated: Buy | $225 | $192.62 | +16.81% | 29 | May 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25.10 | $12.44 | +101.80% | 6 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $3.91 | +104.60% | 7 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $25 → $21 | $19.39 | +8.30% | 40 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $258 | $235.14 | +9.72% | 24 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $49 → $48 | $23.02 | +108.51% | 4 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $179 → $207 | $163.12 | +26.90% | 42 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $9 → $3.16 | $3.15 | +0.48% | 8 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | $5 → $14 | $13.39 | +4.56% | 18 | Apr 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $94 → $111 | $80.13 | +38.52% | 4 | Apr 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $44 | $33.26 | +32.29% | 45 | Apr 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $48 → $46 | $32.42 | +41.91% | 17 | Apr 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $48 | $26.30 | +82.51% | 3 | Apr 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $43 | $42.45 | +1.30% | 38 | Apr 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $4 → $8 | $6.24 | +28.21% | 13 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $15 → $9 | $9.60 | n/a | 19 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $11 → $12 | $22.86 | n/a | 39 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $4.18 | $7.16 | n/a | 64 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $21 → $18 | $3.29 | n/a | 9 | May 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $1 → $12 | $2.85 | n/a | 12 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | $26 → $17 | $0.64999998 | n/a | 29 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $2 | $0.008 | n/a | 7 | May 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 → $3 | $0.6586 | n/a | 5 | Nov 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 → $175 | $0.0001 | n/a | 7 | May 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | n/a | $25.62 | n/a | 1 | Jan 23, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $8 → $5 | $23.43 | n/a | 16 | Nov 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $3 → $2 | $0.8468 | n/a | 10 | Oct 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $6 | $0.0143 | n/a | 1 | Nov 11, 2013 |
Viatris
Jun 4, 2026
Maintained: Hold
Price Target: $12
Current: $15.93
Upside: -24.67%
Supernus Pharmaceuticals
Jun 4, 2026
Maintained: Buy
Price Target: $66
Current: $44.57
Upside: +48.10%
Amneal Pharmaceuticals
Jun 4, 2026
Maintained: Buy
Price Target: $17
Current: $13.71
Upside: +24.00%
Bristol-Myers Squibb Company
Jun 3, 2026
Reiterated: Buy
Price Target: $75
Current: $55.57
Upside: +34.96%
Jazz Pharmaceuticals
Jun 2, 2026
Reiterated: Buy
Price Target: $301
Current: $232.04
Upside: +29.72%
AbbVie
Jun 2, 2026
Reiterated: Buy
Price Target: $298
Current: $223.07
Upside: +33.59%
Corcept Therapeutics
Jun 1, 2026
Reiterated: Buy
Price Target: $88
Current: $73.33
Upside: +20.01%
Teva Pharmaceutical Industries
Jun 1, 2026
Reiterated: Buy
Price Target: $42
Current: $33.26
Upside: +26.28%
Amgen
May 29, 2026
Reiterated: Buy
Price Target: $427
Current: $345.73
Upside: +23.51%
Biogen
May 29, 2026
Reiterated: Buy
Price Target: $225
Current: $192.62
Upside: +16.81%
May 15, 2026
Reiterated: Buy
Price Target: $25.10
Current: $12.44
Upside: +101.80%
May 15, 2026
Reiterated: Buy
Price Target: $8
Current: $3.91
Upside: +104.60%
May 11, 2026
Maintained: Hold
Price Target: $25 → $21
Current: $19.39
Upside: +8.30%
May 11, 2026
Reiterated: Buy
Price Target: $258
Current: $235.14
Upside: +9.72%
May 8, 2026
Reiterated: Buy
Price Target: $49 → $48
Current: $23.02
Upside: +108.51%
May 6, 2026
Reiterated: Buy
Price Target: $179 → $207
Current: $163.12
Upside: +26.90%
May 1, 2026
Downgraded: Hold
Price Target: $9 → $3.16
Current: $3.15
Upside: +0.48%
Apr 28, 2026
Upgraded: Hold
Price Target: $5 → $14
Current: $13.39
Upside: +4.56%
Apr 23, 2026
Maintained: Buy
Price Target: $94 → $111
Current: $80.13
Upside: +38.52%
Apr 23, 2026
Maintained: Hold
Price Target: $44
Current: $33.26
Upside: +32.29%
Apr 22, 2026
Reiterated: Buy
Price Target: $48 → $46
Current: $32.42
Upside: +41.91%
Apr 20, 2026
Reiterated: Buy
Price Target: $48
Current: $26.30
Upside: +82.51%
Apr 13, 2026
Reiterated: Buy
Price Target: $43
Current: $42.45
Upside: +1.30%
Nov 7, 2025
Maintained: Hold
Price Target: $4 → $8
Current: $6.24
Upside: +28.21%
Mar 21, 2025
Downgraded: Hold
Price Target: $15 → $9
Current: $9.60
Upside: n/a
Nov 7, 2024
Reiterated: Hold
Price Target: $11 → $12
Current: $22.86
Upside: n/a
Oct 31, 2024
Reiterated: Sell
Price Target: $4.18
Current: $7.16
Upside: n/a
May 22, 2024
Reiterated: Buy
Price Target: $21 → $18
Current: $3.29
Upside: n/a
May 14, 2024
Reiterated: Hold
Price Target: $1 → $12
Current: $2.85
Upside: n/a
Aug 9, 2023
Downgraded: Sell
Price Target: $26 → $17
Current: $0.64999998
Upside: n/a
May 25, 2022
Maintained: Buy
Price Target: $2
Current: $0.008
Upside: n/a
Nov 10, 2021
Reiterated: Buy
Price Target: $20 → $3
Current: $0.6586
Upside: n/a
May 6, 2021
Maintained: Buy
Price Target: $6 → $175
Current: $0.0001
Upside: n/a
Jan 23, 2019
Upgraded: Hold
Price Target: n/a
Current: $25.62
Upside: n/a
Nov 8, 2018
Reiterated: Hold
Price Target: $8 → $5
Current: $23.43
Upside: n/a
Oct 12, 2017
Reiterated: Hold
Price Target: $3 → $2
Current: $0.8468
Upside: n/a
Nov 11, 2013
Initiated Coverage: Buy
Price Target: $6
Current: $0.0143
Upside: n/a